6th Jan 2022 16:22
BiVictrix Therapeutics PLC - Macclesfield, England-based drug development company specialising in cancer treatments - Appoints Glyn Baker as chief financial officer in a non-board role.
Prior to this, Baker was establishing a new Cambridge, UK-based start-up focused on neurodegenerative disease, and before that was finance director of drug discovery firm Inflazome Ltd.
"We are delighted to welcome Glyn Baker to BiVictriX as Chief Financial Officer. Glyn has amassed significant expertise in Finance and M&A over the last 20 years with some impressive accomplishments. This knowledge, coupled with his contacts, will be invaluable as we look to grow our business and progress the development of our Bi-Cygni therapeutics," said Chief Executive Officer Tiffany Thorn.
Current stock price: 30.97 pence, up 5.0% on Thursday
12-month change: up 21%
By Dayo Laniyan; [email protected]
Copyright 2022 Alliance News Limited. All Rights Reserved.
Related Shares:
BVX.L